Literature DB >> 24355916

Hostile takeover: fungal protein promotes host cell invasion.

J Andrew Alspaugh.   

Abstract

The ability to suppress the immune system has lead to great advances in transplant technology and treatment of autoimmune diseases. Unfortunately, the immunosuppression of these patients has led to the rise of opportunistic infections by organisms that are recalcitrant to current prophylactic strategies. One such example is the increase of mucormycosis, an invasive infection caused by filamentous fungi of the order Mucorales. In this issue of the JCI, Gebremariam and colleagues determined that spore coat homolog (CotH) proteins are required for angioinvasion and that these proteins are unique to Mucorales. Their findings provide a potential therapeutic target for prevention and treatment of mucormycosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24355916      PMCID: PMC3871258          DOI: 10.1172/JCI73585

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  12 in total

1.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

Review 2.  Allergy and immunity to fungal infections and colonization.

Authors:  R Crameri; K Blaser
Journal:  Eur Respir J       Date:  2002-01       Impact factor: 16.671

3.  Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology.

Authors:  J L Frater; G S Hall; G W Procop
Journal:  Arch Pathol Lab Med       Date:  2001-03       Impact factor: 5.534

4.  The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.

Authors:  Mingfu Liu; Brad Spellberg; Quynh T Phan; Yue Fu; Yong Fu; Amy S Lee; John E Edwards; Scott G Filler; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

Review 5.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

Authors:  Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2005-07-29       Impact factor: 9.079

6.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

Authors:  Dimitrios P Kontoyiannis; Michail S Lionakis; Russell E Lewis; Georgios Chamilos; Mimi Healy; Cheryl Perego; Amar Safdar; Hagop Kantarjian; Richard Champlin; Thomas J Walsh; Issam I Raad
Journal:  J Infect Dis       Date:  2005-03-16       Impact factor: 5.226

7.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

8.  Increasing incidence of mucormycosis in University Hospital, Belgium.

Authors:  Veroniek Saegeman; Johan Maertens; Wouter Meersseman; Isabel Spriet; Eric Verbeken; Katrien Lagrou
Journal:  Emerg Infect Dis       Date:  2010-09       Impact factor: 6.883

9.  Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.

Authors:  Dounia Bitar; Dieter Van Cauteren; Fanny Lanternier; Eric Dannaoui; Didier Che; Francoise Dromer; Jean Claude Desenclos; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2009-09       Impact factor: 6.883

10.  Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses.

Authors:  Teresa R O'Meara; Stephanie M Holmer; Kyla Selvig; Fred Dietrich; J Andrew Alspaugh
Journal:  MBio       Date:  2013-01-15       Impact factor: 7.867

View more
  4 in total

1.  Sensitivity of liquid-based cytology in the diagnosis of mucormycosis in COVID-19 treated patients.

Authors:  Rabish Kumar; Meeta Singh; Tanu Sagar; M Bharanidharan; Nita Khurana; Vikas Kumar; Ravi Meher; Vikas Malhotra; Ruchi Goel; Sonal Saxena; Jyoti Kumar
Journal:  Cytopathology       Date:  2022-04-18       Impact factor: 1.286

Review 2.  Mucormycosis co-infection in COVID-19 patients: An update.

Authors:  Abdullah S Alkhamiss; Ahmed A Ahmed; Zafar Rasheed; Ruqaih Alghsham; Ali Shariq; Thamir Alsaeed; Sami A Althwab; Suliman Alsagaby; Abdullah S M Aljohani; Fahad A Alhumaydhi; Sharifa K Alduraibi; Alaa K Alduraibi; Homaidan T Alhomaidan; Khaled S Allemailem; Raya A Alharbi; Samar A Alamro; Arwa M Alqusayer; Sahim A Alharbi; Thekra A Alharby; Mona S Almujaydil; Ayman M Mousa; Sultan A Alghaniam; Abdulrhman A Alghunaim; Rana Alghamdi; Nelson Fernández; Waleed Al Abdulmonem
Journal:  Open Life Sci       Date:  2022-08-10       Impact factor: 1.311

Review 3.  Genes, Pathways, and Mechanisms Involved in the Virulence of Mucorales.

Authors:  Carlos Lax; Carlos Pérez-Arques; María Isabel Navarro-Mendoza; José Tomás Cánovas-Márquez; Ghizlane Tahiri; José Antonio Pérez-Ruiz; Macario Osorio-Concepción; Laura Murcia-Flores; Eusebio Navarro; Victoriano Garre; Francisco Esteban Nicolás
Journal:  Genes (Basel)       Date:  2020-03-16       Impact factor: 4.096

Review 4.  Resolving the equation between mucormycosis and COVID-19 disease.

Authors:  Ritu Pasrija; Mohammad Naime
Journal:  Mol Biol Rep       Date:  2022-01-22       Impact factor: 2.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.